
Marcus Schmitt-Egenolf

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4243346/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Peripheral blood dendritic cells express Fc epsilon RI as a complex composed of Fc epsilon RI alpha- and Fc epsilon RI gamma-chains and can use this receptor for IgE-mediated allergen presentation. Journal of Immunology, 1996, 157, 607-16.	0.4	232
2	Survival, maturation, and function of CD11c- and CD11c+ peripheral blood dendritic cells are differentially regulated by cytokines. Journal of Immunology, 1999, 163, 3250-9.	0.4	175
3	EuroGuiDerm Guideline on the systemic treatment of Psoriasis vulgaris – Part 1: treatment and monitoring recommendations. Journal of the European Academy of Dermatology and Venereology, 2020, 34, 2461-2498.	1.3	149
4	Genomewide Scan in German Families Reveals Evidence for a Novel Psoriasis-Susceptibility Locus on Chromosome 19p13. American Journal of Human Genetics, 2000, 67, 1020-1024.	2.6	129
5	Periodontal Ehlers-Danlos Syndrome Is Caused by Mutations in C1R and C1S , which Encode Subcomponents C1r and C1s of Complement. American Journal of Human Genetics, 2016, 99, 1005-1014.	2.6	100
6	Severity of Psoriasis Differs Between Men and Women: A Study of the Clinical Outcome Measure Psoriasis Area and Severity Index (PASI) in 5438 Swedish Register Patients. American Journal of Clinical Dermatology, 2017, 18, 583-590.	3.3	99
7	Familial Juvenile Onset Psoriasis Is Associated with the Human Leukocyte Antigen (HLA) Class I side of the Extended Haplotype Cw6-B57-DRB1*0701-DQA1*0201-DQB1*0303: A Population- And Family-Based Study. Journal of Investigative Dermatology, 1996, 106, 711-714.	0.3	95
8	EuroGuiDerm Guideline on the systemic treatment of Psoriasis vulgaris – Part 2: specific clinical and comorbid situations. Journal of the European Academy of Dermatology and Venereology, 2021, 35, 281-317.	1.3	84
9	The Higher Proportion of Men with Psoriasis Treated with Biologics May Be Explained by More Severe Disease in Men. PLoS ONE, 2013, 8, e63619.	1.1	82
10	Oligonucleotide Typing Reveals Association of Type I Psoriasis with the HLA-DRB1*0701/2, -DQA* 0201, -DQB1*0303 Extended Haplotype. Journal of Investigative Dermatology, 1993, 100, 749-752.	0.3	71
11	Association between interleukin-1 receptor antagonist (IL-1ra) gene polymorphism and early and late-onset psoriasis. British Journal of Dermatology, 1997, 136, 147-148.	1.4	65
12	Psoriasis Therapy in Real Life: The Need for Registries. Dermatology, 2006, 213, 327-330.	0.9	56
13	Analysis of three outcome measures in moderate to severe psoriasis: a registry-based study of 2450 patients. British Journal of Dermatology, 2012, 166, 797-802.	1.4	54
14	National Registries of Systemic Treatment for Psoriasis and the European â€~Psonet' Initiative. Dermatology, 2009, 218, 347-356.	0.9	50
15	PsoReg – The Swedish Registry for Systemic Psoriasis Treatment. Dermatology, 2007, 214, 112-117.	0.9	47
16	Switch to Biological Agent in Psoriasis Significantly Improved Clinical and Patient-Reported Outcomes in Real-World Practice. Dermatology, 2012, 225, 326-332.	0.9	45
17	Challenges for Synthesising Data in a Network of Registries for Systemic Psoriasis Therapies. Dermatology, 2012, 224, 236-243.	0.9	43
18	Antiâ€TNF treatment during pregnancy and birth outcomes: A populationâ€based study from Denmark, Finland, and Sweden. Pharmacoepidemiology and Drug Safety, 2020, 29, 316-327.	0.9	43

#	Article	IF	CITATIONS
19	Polymorphism in an HLA linked proteasome gene influences phenotypic expression of disease in HLA-B27 positive individuals. Journal of Rheumatology, 1994, 21, 665-9.	1.0	40
20	Decision for biological treatment in real life is more strongly associated with the Psoriasis Area and Severity Index (<scp>PASI</scp>) than with the Dermatology Life Quality Index (<scp>DLQI</scp>). Journal of the European Academy of Dermatology and Venereology, 2015, 29, 452-456.	1.3	38
21	EDAR mutation in autosomal dominant hypohidrotic ectodermal dysplasia in two Swedish families. BMC Medical Genetics, 2006, 7, 80.	2.1	29
22	Comparative association analysis reveals that corneodesmosin is more closely associated with psoriasis than HLA-Cw*0602-B*5701 in German families. Tissue Antigens, 2001, 57, 440-446.	1.0	28
23	Prevalence and incidence of generalized pustular psoriasis in Sweden: a populationâ€based register study*. British Journal of Dermatology, 2022, 186, 970-976.	1.4	27
24	Association scan of the novel psoriasis susceptibility region on chromosome 19: evidence for both susceptible and protective loci. Experimental Dermatology, 2003, 12, 490-496.	1.4	26
25	Complete skin clearance and Psoriasis Area and Severity Index response rates in clinical practice: predictors, healthâ€related quality of life improvements and implications for treatment goals. British Journal of Dermatology, 2020, 182, 965-973.	1.4	26
26	Interleukin-10 promoter polymorphism IL10.G and familial early onset psoriasis. British Journal of Dermatology, 2003, 149, 381-385.	1.4	25
27	Malignant melanoma: gender patterns in care seeking for suspect marks. Journal of Clinical Nursing, 2011, 20, 2676-2684.	1.4	25
28	Evaluating equality in psoriasis healthcare: a cohort study of the impact of age on prescription of biologics. British Journal of Dermatology, 2016, 174, 579-587.	1.4	25
29	Paediatric infections in the first 3 years of life after maternal antiâ€TNF treatment during pregnancy. Alimentary Pharmacology and Therapeutics, 2020, 52, 843-854.	1.9	25
30	PERB11 (MIC): a polymorphic MHC gene is expressed in skin and single nucleotide polymorphisms are associated with psoriasis. Clinical and Experimental Immunology, 2000, 119, 553-558.	1.1	22
31	Drug Persistence of Biologic Treatments in Psoriasis: A Swedish National Population Study. Dermatology and Therapy, 2021, 11, 2107-2121.	1.4	22
32	Systemic psoriasis therapy shows high between-country variation: a sign of unwarranted variation? Cross-sectional analysis of baseline data from the PSONET registries. British Journal of Dermatology, 2013, 169, 710-714.	1.4	19
33	Analysis of TAP2 and HLA-DP gene polymorphism in Psoriasis. Human Immunology, 1994, 40, 299-302.	1.2	18
34	Sustained Psoriasis Area and Severity Index, Dermatology Life Quality Index and EuroQolâ€5D response of biological treatment in psoriasis: 10 years of realâ€world data in the Swedish National Psoriasis Register. British Journal of Dermatology, 2018, 178, 245-252.	1.4	17
35	Promoter Polymorphism at –238 of the Tumor Necrosis Factor Alpha Gene is Not Associated with Early Onset Psoriasis when Tested by the Transmission Disequilibrium Test. Journal of Investigative Dermatology, 1999, 112, 514-515.	0.3	16
36	How is disease severity associated with quality of life in psoriasis patients? Evidence from a longitudinal population-based study in Sweden. Health and Quality of Life Outcomes, 2017, 15, 151.	1.0	16

MARCUS SCHMITT-EGENOLF

#	Article	IF	CITATIONS
37	Patients' decision making in seeking care for suspected malignant melanoma. Journal of Nursing and Healthcare of Chronic Illness, 2010, 2, 164-173.	0.5	15
38	Association of Skin Psoriasis and Somatic Comorbidity With the Development of Psychiatric Illness in a Nationwide Swedish Study. JAMA Dermatology, 2020, 156, 795.	2.0	15
39	Regional Differences in the Prescription of Biologics for Psoriasis in Sweden: A Register-Based Study of 4168 Patients. BioDrugs, 2017, 31, 75-82.	2.2	14
40	Long-Term Risk of Skin Cancer and Lymphoma in Users of Topical Tacrolimus and Pimecrolimus: Final Results from the Extension of the Cohort Study Protopic Joint European Longitudinal Lymphoma and Skin Cancer Evaluation (JOELLE). Clinical Epidemiology, 2021, Volume 13, 1141-1153.	1.5	13
41	Type I and Type II psoriasis Show a Similar Usage of T-Cell Receptor Variable Regions. Journal of Investigative Dermatology, 1991, 97, 1053-1056.	0.3	12
42	Resource Use in Patients with Psoriasis After the Introduction of Biologics in Sweden. Acta Dermato-Venereologica, 2015, 95, 156-161.	0.6	12
43	Healthcare Provider Type and Switch to Biologics in Psoriasis: Evidence from Real-World Practice. BioDrugs, 2016, 30, 145-151.	2.2	12
44	Health-Care Delay in Malignant Melanoma: Various Pathways to Diagnosis and Treatment. Dermatology Research and Practice, 2014, 2014, 1-6.	0.3	11
45	Register-Based Evaluation of Relative Effectiveness of New Therapies: Biologics Versus Conventional Agents in Treatment of Psoriasis in Sweden. BioDrugs, 2015, 29, 389-398.	2.2	10
46	Coping styles in decision-making among men and women diagnosed with malignant melanoma. Journal of Health Psychology, 2013, 18, 1445-1455.	1.3	9
47	EDAR-induced hypohidrotic ectodermal dysplasia: a clinical study on signs and symptoms in individuals with a heterozygous c.1072C > T mutation. BMC Medical Genetics, 2014, 15, 57.	2.1	9
48	Real-World Outcome Analysis of Continuously and Intermittently Treated Patients with Moderate to Severe Psoriasis after Switching to a Biologic Agent. Dermatology, 2015, 230, 347-353.	0.9	8
49	Prevalence and incidence of palmoplantar pustulosis in Sweden: a populationâ€based register study*. British Journal of Dermatology, 2021, 185, 945-951.	1.4	8
50	Economic Burden of Generalized Pustular Psoriasis in Sweden: A Population-Based Register Study. Psoriasis: Targets and Therapy, 2022, Volume 12, 89-98.	1.2	8
51	Physical activity and lifestyle improvement in the management of psoriasis. British Journal of Dermatology, 2016, 175, 452-453.	1.4	7
52	Real-world outcomes in 2646 psoriasis patients: one in five has PASI ≥10 and/or DLQI ≥10 under ongoing systemic therapy. Journal of Dermatological Treatment, 2017, 28, 500-504.	1.1	7
53	Hair shaft structures in EDAR induced ectodermal dysplasia. BMC Medical Genetics, 2015, 16, 79.	2.1	5
54	Association and Linkage of Human Leukocyte Antigens with Psoriasis – Revisited. Transfusion Medicine and Hemotherapy, 2002, 29, 326-330.	0.7	4

#	Article	IF	CITATIONS
55	Complete skin clearance and beyond. British Journal of Dermatology, 2021, 184, 3-4.	1.4	3
56	Switching Biologicals: Switching TNFα Antagonists in Psoriasis Treatment. Dermatology, 2008, 216, 281-282.	0.9	2
57	Healthâ€related quality of life in patients with melanoma – characterization of a Swedish cohort. British Journal of Dermatology, 2020, 182, 506-508.	1.4	2
58	The Relationship Between Disease Severity and Quality of Life In Patients With Moderate to Severe Psoriasis. Value in Health, 2015, 18, A675.	0.1	1
59	Patient Registries for Safetyness. Methods in Pharmacology and Toxicology, 2018, , 149-164.	0.1	1
60	Perception of information to Swedish melanoma patients in routine clinical practice – a cross-sectional survey. BMC Cancer, 2022, 22, 159.	1.1	1
61	What can we learn from â€~dropouts' in clinical trials?. British Journal of Dermatology, 2018, 178, 318-319.	1.4	0

62 ä¹⁄2¿ç"`ç"Ÿç‰©ç——法治痗é"¶å±'ç—…çš"æŒç»-PASIã€DLQI åŠ EQâ€5D 结æžœ:基于ç'žå…,囹⁄2å®¶é"¶å±İç4…ç™»ð®°çš"åå¹′œ

63	Severity of psoriasis – Time to disentangle severity from symptom control. British Journal of Dermatology, 2022, , .	1.4	0
64	Diverse research designs are needed for population health: Lessons from Maslow. Lifestyle Medicine, 2022, 3, .	0.3	0